Cancer Education and Research Institute
Worldwide Access to Research, High-Quality Care, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2021
      • Press Releases 2020
      • Press Releases 2019
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • Patient Education
    • All about cancer
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types-Education
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
    • CERI Personalized Patient Program
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

Cancer Education and Research Institute (CERI)'s Cancer Education Programs 

Tweet
Follow @canceredinst

Treatment for Ovarian Cancer

Rubraca (rucaparib):

Treatment for ovarian cancer - Cancer Education and Research Institute (CERI)
On December 19, 2016, the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) to treat women with advanced ovarian cancer that has BRCA gene mutation. 
BRCA genes are involved with repairing damaged DNA. Thus, under normal conditions, they work to prevent tumor development. However, mutations (abnormalities) of these genes may lead to certain cancers, which include breast and ovarian cancers. Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme (a protein involved in catalytic reactions in our body), which is involved in repairing damaged DNA. By blocking this enzyme through Rubraca, DNA inside the cancerous cells with damaged/mutated/abnormal BRCA genes may be less likely to be repaired by the enzyme, which leads to cell death and potentially a slow-down or inhibition of tumor growth.

Common side effects of Rubraca include nausea, fatigue, vomiting, low levels of red blood cells (anemia), abdominal pain, unusual taste sensation (dysgeusia), constipation, decreased appetite, diarrhea, low levels of blood platelets (thrombocytopenia) and trouble breathing (dyspnea).  Rubraca is associated with serious risks, such as bone marrow problems (myelodysplastic syndrome), a type of cancer of the blood called acute myeloid leukemia and fetal harm.


Rubraca is marketed by Clovis Oncology, Inc. based in Boulder, Colorado. The FoundationFocus CDxBRCA companion diagnostic is marketed by Foundation Medicine, Inc. of Cambridge, Massachusetts.
Treatment for ovarian cancer - Cancer Education and Research Institute (CERI)
For more information visit the FDA's website: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm

To learn more about ovarian cancer, read our articles, watch our videos: 

  • LATEST: NEW TREATMENT FOR OVARIAN CANCER
  • OVARIAN CANCER TREATMENT
  • OVARIAN CANCER STAGES
  • OVARIAN CANCER DIAGNOSIS
  • OVARIAN CANCER SYMPTOMS
  • ​OVARIAN CANCER FACTS​
  • What is OVARIAN CANCER? INTRO
  • Early diagnosis procedures: Cervical & Endometrial cancer
  • FDA approved cancer drugs in 2016

#ovariancancer #womenshealth #BRCA #gene #rubraca #rucaparib #FDA #FDAapproval #ovariancancertreatment #cancertreatment #health #cancer #cancerpatients #cancereducation #patienteducation #publiceducation #canceredinstitute
Did you find this article helpful? Please let us know below. Be sure to share it with your loved ones. 

    Help us to serve you better!

Submit

You might also like:

Disclaimer: We can not assume responsibility of misinterpretation of content.
​

👉 Like our Facebook page for daily cancer info: Cancer Education and Research Institute 
👉#canceredinstitute

Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, mission is simple: Cancer Education for All™!  Our Team of cancer experts provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.  

CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education.  Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.  

For any questions or requests, please contact us. ​

Please donate to support our cause - help us continue with our trusted educational programs;
​help us save lives; help us guide and empower cancer patients and their caregivers
:
Cancer Education and Research Institute, fka Cancer Research Simplified, is a registered 501(c)(3) non-profit organization.
​Your donations are tax deductible to the extent permitted by law.
Yes, I'd like to help CERI continue saving lives!

Donate

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2022 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®